<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The adaptive cellular immune response: T cells and cytokines</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The adaptive cellular immune response: T cells and cytokines</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The adaptive cellular immune response: T cells and cytokines</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Heimall, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>T cells regulate the activities cells participating in immune responses. They provide help for antibody production by B cells, and they are also the effectors of antigen-specific cell-mediated immunity (CMI). CMI is important in the elimination of intracellular infections (eg, viruses, mycobacteria, and some bacteria) and aberrantly differentiating cells (eg, neoplasms). CMI also destroys allogeneic cells (graft rejection). In addition, it is involved in cellular autoimmune responses, as well as type IV allergic reactions to drugs and contact dermatitis. Furthermore, T cells activate innate immune cells such as phagocytic cells to become more effective at killing other types of pathogens such as fungi. (See  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology"</a> and  <a class="medical medical_review" href="/z/d/html/5579.html" rel="external">"Overview of autoimmunity"</a> and  <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features", section on 'Type IV reactions'</a> and  <a class="medical medical_review" href="/z/d/html/1727.html" rel="external">"Overview of dermatitis (eczematous dermatoses)", section on 'Allergic contact dermatitis'</a>.)</p><p>T cell receptors (TCRs), in contrast to immunoglobulins, exist only as multimeric membrane-bound complexes and are not secreted intact in soluble form. Also unlike immunoglobulins, TCRs recognize fragments (peptides) of protein or glycoprotein antigens in complexes with major histocompatibility molecules on the surfaces of antigen-presenting cells (APCs, also called accessory cells) or on targets of cytotoxicity. Note the distinction between the processed antigen (peptide) eliciting a response and the major histocompatibility complex (MHC) antigen with which it becomes associated to stimulate peptide-specific T cells. (See  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a> and  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p>The cellular interactions that form the basis of CMI are discussed in this topic review. Related topics and T cell help for antibody production are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a> and  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a> and  <a class="medical medical_review" href="/z/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANTIGEN-PRESENTING CELLS</span><span class="headingEndMark"> — </span>T cell responses are initiated by antigen-presenting cells (APCs), which are reviewed briefly here and discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3982.html" rel="external">"Antigen-presenting cells"</a>.)</p><p>Dendritic cells (DCs) are the predominant class of "professional" APCs [<a href="#rid1">1</a>]. The main subtypes include plasmacytoid DCs (pDCs) and conventional DCs (cDCs). These are further divided into additional subtypes that have distinct surface marker expression, morphology, tissue distribution, and cytokine production. These different types of DCs lead to distinct pathways of T cell stimulation. Monocytes/macrophages may also exert some APC activity, and monocytes may differentiate into DCs.</p><p>Only APCs constitutively express major histocompatibility complex (MHC) class II molecules (which are required for activation of CD4+ T cells) and display the necessary costimulatory signals. The great majority of somatic cells express MHC class I molecules and can serve as targets of CD8+ cytotoxic T cells.</p><p>B cells express MHC class II molecules, which are required to receive T cell help (see  <a class="medical medical_review" href="/z/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>). Although they are not strong enough to activate resting naïve T cells, B cells may stimulate memory T cells. (See <a class="local">'Memory T cells'</a> below.)</p><p>DCs use a system of pattern recognition receptors, such as "Toll-like" receptors (TLRs), that bind to a variety of microbial products, including bacterial lipopolysaccharide, flagellin, and lipopeptides. These receptors stimulate development and migration of immature DCs in the periphery. Under the influence of cytokines and chemokines, DCs mature and migrate into the secondary lymphoid tissues where they interact with T and B cells in T zones of the lymph nodes, Peyer patches, and the spleen. Cysteine-cysteine motif chemokine receptor (CCR) 7 and cysteine-X-cysteine motif receptor (CXCR) 5 both act to assist DC, T, and B cell trafficking to lymphoid tissues [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy"</a>.)</p><p>DCs are highly active in processing and presenting antigen to T cells. Antigen is taken up via several means (macropinocytosis, in immune complexes via immunoglobulin G [IgG] Fc receptors, etc). The antigen is then degraded, and peptides are loaded onto MHC class I or class II molecules. Intracellular-derived antigens (intracellular self-proteins or products of organisms that replicate intracellularly) are predominantly presented via MHC class I molecules and extracellular antigens mainly via MHC class II molecules. However, there is significant overlap in these pathways. (See  <a class="medical medical_review" href="/z/d/html/3969.html" rel="external">"Major histocompatibility complex (MHC) structure and function"</a>.)</p><p class="headingAnchor" id="H4174039912"><span class="h1">CYTOKINES</span><span class="headingEndMark"> — </span>Immune cells produce a variety of products that allow them to communicate with each other and orchestrate an explosive, yet self-limited attack. Cytokines are hormone-like glycoproteins that enable immune cells to communicate with one another by either direct contact or through the secretion of soluble mediators. They play an integral role in the initiation, perpetuation, and subsequent downregulation of the immune response  (<a class="graphic graphic_table graphicRef69910" href="/z/d/graphic/69910.html" rel="external">table 1</a>).</p><p>Direct cell-cell contact regulates immune function of adjacent cells by a variety of mechanisms, including membrane-bound cytokines such as tumor necrosis factor (TNF) alpha. In contrast, release of soluble mediators into the environment permits cells to exert influence at a distant site within the tissue. In some cases, cytokines can even reach distant cells in other organs via the peripheral circulation. For instance, interleukin (IL) 6 produced at a local inflammatory site can enhance liver acute-phase protein production. Soluble cytokines bind to a specific receptor on the surface of target cells and transduce a signal that alters cellular function.</p><p>The migration of immune cells is accomplished by a highly redundant family of cytokines known as chemokines. These factors, which are classified by their amino acid sequence and their inflammatory and immune regulatory homeostatic roles, bind to specific surface receptors that induce cells to migrate into tissues [<a href="#rid3">3</a>]. However, there is plasticity to the relationship of chemokines binding to their receptors such that loss of a single chemokine receptor does not lead to a profound loss in the ability of immune cells to migrate and carry out their intended functions [<a href="#rid4">4</a>]. The roles of chemokines include induction of cellular migration, local cellular activation and survival, and homeostatic regulation of immune cells.</p><p class="headingAnchor" id="H4"><span class="h1">T CELL ACTIVATION AND FUNCTIONS</span></p><p class="headingAnchor" id="H5"><span class="h2">T cell receptor-CD3 complex</span><span class="headingEndMark"> — </span>The T cell receptor (TCR) alpha-beta (TCR2) or gamma-delta (TCR1) heterodimer is noncovalently associated with the CD3 complex on the cell membrane. There are four types of CD3 subunits: gamma, delta, epsilon, and zeta. CD3 complex is comprised of gamma-epsilon and delta-epsilon heterodimers and a zeta homodimer in most cells. The gamma and delta chains of CD3 are distinct from the gamma and delta forms of the TCR itself. The CD3 complex is expressed on all T cells. The complex has a critical role in transducing a signal of TCR contact across the lymphocyte membrane  (<a class="graphic graphic_figure graphicRef69555" href="/z/d/graphic/69555.html" rel="external">figure 1</a>). The interaction of the TCR with a complementary complex of peptide plus major histocompatibility complex (peptide-MHC) forms the basis of the antigen specificity of T cell activation by antigen-presenting cells (APCs) and target cell recognition in cell-mediated immunity (CMI). (See  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">T cell accessory molecules</span><span class="headingEndMark"> — </span>T cells are categorized based upon cell surface expression of one of two coreceptor molecules, either cluster of differentiation (CD) 4 or CD8. CD4 and CD8 have great importance for T cell development and for antigen recognition and activation of mature T cells (see  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>). CD4+ cells recognize antigen presented by a MHC class II, while CD8+ cells recognize antigen presented by an MHC class I.</p><p>There are a host of additional cell surface molecules that play roles in T cell interactions with other cells including T cell activation by APCs, T cell regulation of other T cells and B cells, and cytotoxic T cell killing. Some of these are adhesion molecules, others are mainly transducers of activating or inhibitory signals, and several have multiple functions. Some of these T cell accessory molecules are summarized in the table  (<a class="graphic graphic_table graphicRef72603" href="/z/d/graphic/72603.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H7"><span class="h2">T cell circulation</span><span class="headingEndMark"> — </span>Upon their egress from the thymus, naïve T cells circulate throughout the body in both the blood and lymph fluids. Naïve T cells circulating through secondary lymphoid tissues, such as spleen, lymph nodes, and Peyer's patches in the intestine, encounter dendritic cells (DCs) that have similarly migrated to these tissues to present antigens. The naïve T cells "scan" the antigens presented by the DCs. When an antigen-MHC complex of suitable affinity is identified, the naïve T cells are activated [<a href="#rid5">5</a>]. Since naïve T cells continually recirculate through the blood, spleen, lymph, lymph nodes, and other tissues [<a href="#rid6">6</a>] throughout the body, they are able to sample antigens derived from a wide range of distinct anatomic sites.</p><p>Following engagement of the appropriate complementary complex, the activated naïve T cells proliferate. Activated T cells also migrate toward the periphery of the T cell-rich areas in the secondary lymphoid organs to facilitate contact with the B cell-rich areas. This permits interactions with antigen-specific B cells, thereby providing T cell help for antibody production. (See  <a class="medical medical_review" href="/z/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p>Activated naïve T cells may either become effector T cells, which are then able to further differentiate to memory cells, or they may directly differentiate to become memory T cells. Most effector T cells will then migrate from the lymphoid organs into the peripheral circulation and tissues. This permits effector T cells to reach sites of infection.</p><p class="headingAnchor" id="H15282574"><span class="h2">T cell activation via the two-signal model</span><span class="headingEndMark"> — </span>The paradigm for T cell activation is the so-called "two-signal" model  (<a class="graphic graphic_figure graphicRef69555" href="/z/d/graphic/69555.html" rel="external">figure 1</a>). All of the cell surface molecules listed in the table may play a role in T cell activation  (<a class="graphic graphic_table graphicRef72603" href="/z/d/graphic/72603.html" rel="external">table 2</a>). During intercellular contact, many of these molecules interact with cytoskeletal elements and are organized into specific regions within the zone of contact named the "immunologic synapse"  (<a class="graphic graphic_figure graphicRef69555" href="/z/d/graphic/69555.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>].</p><p>The two-signal model of T cell activation includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Signal 1 derives from contact of TCR-CD3 with a peptide-MHC complex.</p><p></p><p class="bulletIndent1">It is possible, particularly where agonist (foreign) peptide-MHC complexes occur at very low density on the APC surface, that endogenous (self) peptide-MHC complexes also participate in the initiation of the immunologic synapse [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signal 2 derives from costimulatory pathways.</p><p></p><p>A tremendously complex cascade of events within the cytoplasm ensues upon receptor and costimulator ligation  (<a class="graphic graphic_figure graphicRef66727" href="/z/d/graphic/66727.html" rel="external">figure 2</a>) [<a href="#rid9">9</a>]. TCR signaling is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15794.html" rel="external">"T cell receptor signaling"</a>.)</p><p>Binding of TCR-CD3 <strong>without</strong> engaging any costimulating molecules leads to a state of anergy (unresponsiveness or refractoriness to activation) and possibly even to deletion by apoptosis (death) [<a href="#rid10">10</a>]. This may be an important mechanism in T cell tolerance. (See  <a class="medical medical_review" href="/z/d/html/5594.html" rel="external">"Apoptosis and autoimmune disease"</a>.)</p><p>The mechanism by which costimulation leads to activation rather than anergy is unknown. The interaction between CD28 expressed on T cells and CD80 and CD86 (B7-1 and B7-2) expressed on APCs is a very potent costimulatory system [<a href="#rid10">10</a>]. T cells express CD154 (CD40 ligand, CD40L) following activation via the TCR. CD40L binds to CD40 expressed on the APC surface and induces expression of CD80 and CD86 by the APC. Binding of these to CD28 on a resting T cell will not activate the cell, but, once a T cell has been "primed" by antigen exposure, ligation of CD28 can trigger production of interleukin (IL) 2 and cellular proliferation. The simultaneous production of the cytokine IL-2 and a component of its high-affinity receptor (IL-2R-alpha or CD25) initiates a positive feedback loop that is important for T cell proliferation.</p><p>Inducible T cell costimulator (ICOS) is a CD28 homolog that is inducibly expressed on activated T cells [<a href="#rid10">10</a>]. Interaction with ICOS ligand (ICOS-L, a B7 homolog) may augment T cell activation. However, ICOS also appears to have other roles in modulating IL-10 production by regulatory T cells (Tregs) and inhibiting development of T helper type 17 (Th17) cells. (See <a class="local">'Treg'</a> below and <a class="local">'Th17'</a> below.)</p><p>A wide variety of additional signaling molecules expressed on T cells and APCs influence the activation or suppression and differentiation of T cells into effector/memory or regulatory cells [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H8"><span class="h3">CD4+ T cell activation</span><span class="headingEndMark"> — </span>The following sequence of events takes place during activation of CD4+ T cells:</p><p class="bulletIndent1"><span class="glyph">●</span>DCs capture and process antigen from peripheral sites. They then migrate into lymph nodes and develop into mature APCs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Naïve T cells "scan" DCs with their TCR, looking for complementary peptide-MHC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antigen recognition triggers a complex cascade of intercellular membrane glycoprotein contacts and intracellular biochemical signals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The T cell-APC (or other cell) interaction is modulated by alterations in the expression of surface molecules and cytokine secretion by both cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific characteristics of the cytokine milieu and the combination of signals results in either activation or tolerization of the T cell. It also determines the effector phenotype of an activated cell.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The activated/effector T cell may then migrate into peripheral tissues or undergo further interactions with other cells (eg, B cells) within lymphoid tissues.</p><p></p><p class="headingAnchor" id="H11"><span class="h4">Cytokine profiles and functions of CD4+ T helper cell subsets</span><span class="headingEndMark"> — </span>Activated CD4+ T cells are subdivided into distinct functional categories depending upon the profile of secreted cytokines  (<a class="graphic graphic_figure graphicRef58150" href="/z/d/graphic/58150.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef101256" href="/z/d/graphic/101256.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef69910" href="/z/d/graphic/69910.html" rel="external">table 1</a>) [<a href="#rid11">11</a>]. The conditions under which a T cell is stimulated have great influence on the functional phenotype of the activated cell. The route by which antigens enter the body (eg, skin, gut, etc), the form of the antigen (inert molecules, living microorganisms), and the amount of antigen are all important factors that impact the differentiation to these functional T cell subsets.</p><p>At the cellular level during T cell stimulation, the degree of TCR occupancy, the activity of various costimulatory pathways, and the presence of certain cytokines all influence the phenotype of activated cells. As examples, IL-12 and interferon (IFN) gamma are the cytokines that drive T helper type 1 (Th1) cell development, while IL-4 is critical for determining T helper type 2 (Th2) development  (<a class="graphic graphic_table graphicRef69910" href="/z/d/graphic/69910.html" rel="external">table 1</a>).</p><p>These helper T cell subpopulations are not easily distinguished with respect to surface markers. Thus, they are usually identified by their cytokine production. In general, each of these cytokine production subtypes does not amount to more than 2 to 5 percent of the T cells in circulation, usually less. These proportions are highly variable and depend upon many factors such as chronic and/or acute infection and inflammation, the genetic makeup of the individual, and modifying environmental factors. Proportions of one or more subsets may be higher in lymphoid or other tissues, again depending upon the specific tissue and ongoing immunologic processes. (See  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p>Several subsets have been distinguished for CD4+ T cells. These can be grouped into those associated with effector activities (Th1, Th2, Th9, Th17, Th22, and follicular helper T cells [Tfh]) and those with regulatory activities (natural regulatory T cell [nTreg], induced regulatory T cell [iTreg (type 1 regulatory T cell [Tr1])], Th3)  (<a class="graphic graphic_figure graphicRef58150" href="/z/d/graphic/58150.html" rel="external">figure 3</a>) [<a href="#rid11">11</a>]. The Th1 and Th2 patterns have been most extensively studied. These patterns are to some degree mutually exclusive, as one pattern often clearly predominates in the context of a particular immune response.</p><p class="headingAnchor" id="H12"><span class="h5">Th1</span><span class="headingEndMark"> — </span>T helper type 1 (Th1) responses promote production of opsonizing antibodies (eg, IgG1) and induction of cellular cytotoxicity and macrophage activation. Th1 cells secrete IFN-gamma and IL-2 but not IL-4. They activate macrophages and help in the eradication of intracellular micro-organisms, such as mycobacteria and viruses. Th1 cells also promote cytotoxic T cell development and delayed-type hypersensitivity (DTH) reactions. Hence, Th1 cells are proinflammatory and may be involved in the pathogenesis and maintenance of some autoimmune diseases.</p><p>Th1 cells express both chains of the IL-12 receptor (IL-12-R-beta-1 and IL-12-R-beta-2) [<a href="#rid12">12,13</a>], as well as cysteine-X-cysteine motif receptor (CXCR) 3 and cysteine-cysteine motif chemokine receptor 5 (CCR5) [<a href="#rid12">12,14-16</a>]. Th1 responses are promoted by local release of the IL-12 superfamily of cytokines including IL-27, IL-23, and IL-12. IL-12 may favor IFN-gamma release, whereas IL-23 may favor IL-17 release. These responses are further enhanced by IL-15 and IL-18 production by DCs and macrophages.</p><p>T-bet promotes Th1 development by direct induction of IFN-gamma and IL-12-R-beta-2 chain gene transcription [<a href="#rid17">17,18</a>]. In addition, T-bet appears to inhibit IL-4, IL-5, and IL-17 secretion. T-bet may also inhibit Th2 differentiation by preventing GATA-binding protein 3 (GATA3) from interacting with its target DNA [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H13"><span class="h5">Th2</span><span class="headingEndMark"> — </span>T helper type 2 (Th2) cells produce IL-4, IL-5, IL-13, and IL-10 but not IL-2 or IFN-gamma. By virtue of their IL-4 and IL-13 secretion, they are important in the promotion of immunoglobulin E (IgE) synthesis and via IL-5 stimulate eosinophil development. They help mediate immunity against parasitic infestations, particularly helminths, and are pivotal in the development of allergy and asthma [<a href="#rid20">20-22</a>].</p><p>Th2 cells express IL-12-R-beta-1 [<a href="#rid12">12,13</a>] and IL-4 receptors [<a href="#rid23">23</a>]. CCR3, CCR8, and CCR10 are also expressed by Th2 cells [<a href="#rid12">12,14-16</a>]. Th2 responses are favored by synergistic local production of IL-4, IL-33, and IL-18. GATA3 is pivotal for Th2 maturation [<a href="#rid17">17,18</a>].</p><p class="headingAnchor" id="H636962865"><span class="h5">Th9</span><span class="headingEndMark"> — </span>T helper type 9 (Th9) cells produce IL-9 and IL-10. Th9 development from naïve Th cells is mediated by transcription factors signal transducer and activator of transcription (STAT) 6 and PU.1 (binds to a purine-rich DNA sequence called the PU-box) [<a href="#rid24">24,25</a>] in the presence of transforming growth factor (TGF) beta, IL-2, and IL-4. These cells have a role in antitumor immunity, allergy, and autoimmune disease [<a href="#rid26">26</a>]. They are also thought to be important in resistance to parasites and may be involved in asthma and other allergic disease [<a href="#rid27">27,28</a>]. PU.1 has a negative effect on the expression of CD40L in CD4 cells and downregulates IL-21 expression as well, leading to decreased germinal cell B cell expansion and reduced IgG production [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H14"><span class="h5">Th17</span><span class="headingEndMark"> — </span>T helper type 17 (Th17) cells secrete IL-17A, which induces production of proinflammatory cytokines (IL-17F, IL-22, IL-26) and chemokines (CCL20) and recruits neutrophils [<a href="#rid12">12</a>]. Th17 cells appear to be involved in the early response to numerous extracellular pathogens, including bacteria and fungi, and play an important role in driving chronic inflammatory responses in chronic infection, allergy, and autoimmunity [<a href="#rid30">30,31</a>]. They may also play a role in the neutrophil, rather than eosinophil, predominant forms of asthma [<a href="#rid32">32</a>].</p><p>Th17 cells express only IL-12-R-beta-1 [<a href="#rid12">12,13</a>]. Th17 cells express the IL-23 receptor, a heterodimer comprised of IL-12-R-beta-1 and a unique IL-23-R chain, in addition to receptors for IL-6, IL-21, and TGF-beta [<a href="#rid12">12,33</a>]. CCR2 and CCR6 are expressed by Th17 cells [<a href="#rid12">12,14-16</a>]. Retinoid-related orphan receptor gamma t (RORgT) is critical for Th17 maturation [<a href="#rid17">17,18</a>].</p><p class="headingAnchor" id="H636962877"><span class="h5">Th22</span><span class="headingEndMark"> — </span>T helper type 22 (Th22) cell production is upregulated by RORgT and downregulated by Tbet. Th22 cells are a major source of IL-22, although this cytokine is also produced by Th17 cells [<a href="#rid34">34</a>]. When IL-22 is cosecreted with IL-17, the effect tends toward more proinflammatory outcomes, particularly in psoriasis. In asthma and atopic dermatitis, increased frequency of IL-22 cells is associated with increased disease severity. Th22 cells can also have a protective role in mucosal immunity [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H636962889"><span class="h5">Tfh</span><span class="headingEndMark"> — </span>T follicular helper (Tfh) cells are preponderant in germinal centers in secondary lymphoid tissues where they have a prominent role in providing help to B cells for high-affinity antibody production [<a href="#rid36">36-38</a>]. IL-12 may be crucial to Tfh development [<a href="#rid39">39</a>]. Circulating Tfh express high levels of the chemokine receptor CXCR5 [<a href="#rid40">40</a>].</p><p>Naïve CD4 T cells differentiate to Tfh cells when the transcription factor B cell lymphoma 6 protein (BCL6) is expressed along with high levels of CXCR5, which allows these T cells to migrate to and reside in the germinal centers of lymph nodes [<a href="#rid41">41</a>]. Tfh resident in lymph node germinal centers can be characterized by the surface markers CCR7<sup>lo</sup>PSGL1<sup>lo</sup>CXCR5<sup>hi</sup>,PD-1<sup>hi</sup>, ICOS<sup>hi</sup> [<a href="#rid40">40</a>]. The development of Tfh cells is inhibited by B lymphocyte-induced maturation protein 1 (Blimp-1) and STAT5. IL-12, IL-23 and TGF-beta are the initiating cytokines for Tfh differentiation [<a href="#rid39">39</a>]. IL-1 and IL-6 signaling through STAT3 are also important in the differentiation of Tfh. In the presence of appropriate cytokines and B cell interactions, Tfh cells can differentiate into Th1-like, Th2-like, or Th17-like Tfh cells [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H47575556"><span class="h5">Treg</span><span class="headingEndMark"> — </span>T regulatory (Treg) cells are central to the establishment and maintenance of peripheral tolerance. They play a principal role in negative regulation (suppression) of the immune response. Treg cells typically comprise 1 to 2 percent of the total CD4 population, but overall are critically responsible for the suppression of effector CD4 T cell effects through contact inhibition of activity between APC and effector T cells or direct cytotoxicity.</p><p>Development of nTregs is mediated by the transcription factor forkhead box P3 (Foxp3), which leads to surface expression of cytotoxic T lymphocyte antigen 4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), killer cell lectin-like receptor G1 (KLRG1), CD25, and Blimp-1. Treg cells also commonly express CD134 (OX40), CD27, and CD62-L and secrete TGF-beta, IL-10, and also IL-35, a novel member of the IL-12 superfamily [<a href="#rid42">42</a>]. Their effector function is often dependent upon cell contact-mediated cellular suppression. (See <a class="local">'Suppression'</a> below.)</p><p class="headingAnchor" id="H2601516479"><span class="h5">iTreg</span><span class="headingEndMark"> — </span>Induced T regulatory (iTreg) cells can be induced in the periphery after antigen priming in the presence of retinoic acid and TGF-beta.</p><p class="headingAnchor" id="H483358651"><span class="h5">Th3</span><span class="headingEndMark"> — </span>T helper type 3 (Th3) cells are important in mucosal tolerance induction and may promote development and/or maintenance of induced Treg cells [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3863916397"><span class="h3">CD8+ T cell activation</span><span class="headingEndMark"> — </span>Cytotoxic T cells (cytotoxic T lymphocytes [CTLs]), the majority of which express the CD8 coreceptor for MHC class I, are also activated by professional APCs in lymphoid tissues, as are CD4-bearing cells. However, the APC must first be activated by contact with an antigen-specific CD4+ T cell before it is capable of inducing a naïve CD8+ cell to become a full-fledged effector (cytotoxic) T cell [<a href="#rid44">44</a>]. Direct CD4+ T cell help may also be required for primary CD8+ T cell responses in the face of viral challenge, in particular by increasing IFN-gamma and Fas ligand (FasL) expression [<a href="#rid44">44,45</a>].</p><p>As mentioned above, virtually all nucleated cells process cytoplasmic molecules and present them on their surfaces in association with MHC class I molecules (see <a class="local">'Antigen-presenting cells'</a> above). Thus, antigens derived from pathogens that replicate intracellularly are presented in this manner. Professional APCs may also present antigens internalized by phagocytosis via MHC class I molecules [<a href="#rid1">1</a>]. The degree to which MHC molecules bearing antigen cluster on the cell surface appears to affect the sensitivity of T cell recognition [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1857149358"><span class="h4">Cytotoxic T lymphocyte function</span><span class="headingEndMark"> — </span>After acquiring effector function in lymphoid tissues, cytotoxic cells circulate in the periphery, "searching" for infected cells to kill. The first step in lysis is membrane contact between the cytotoxic and target cells presenting antigens specific to the TCR, forming the immunologic synapse. This contact is mediated by the TCR/CD8-MHC class I interaction, as well as by several T cell/target cell adhesion molecule interactions (eg, CD2 with CD58, CD11a/CD18 with CD54CD54 and others) [<a href="#rid47">47</a>].</p><p>Cytotoxicity occurs via two principal mechanisms: granule exocytosis and expression of FasL. In addition to these cytotoxic mechanisms, CTLs also secrete a variety of cytokines, such as IFN-gamma and TNF, that may directly damage target cells or inhibit microbial replication [<a href="#rid47">47</a>]. They also recruit and modulate additional inflammatory effector cells, such as macrophages.</p><p>Natural killer (NK) cells express a cytotoxicity activating molecule called natural killer group 2 D (NKG2D or killer cell lectin-like receptor, subfamily K, member 1 [KLRK1]). Two ligands for NKG2D are MHC class I-like molecules MHC class I chain-related gene A (MICA) and ULBP4 (binding protein 4 for the cytomegalovirus-encoded glycoprotein UL16). CTLs also express NKG2D, and cytotoxicity of these cells can also be promoted by interaction with MICA and ULBP4 [<a href="#rid48">48</a>]. The latent membrane protein 2A (LMP2A) on the surface of Epstein-Barr virus (EBV) transformed cells can reduce expression of or interfere with the interaction of MICA and ULBP4 with NKG2D and inhibit CTL recognition of EBV transformed B cells.</p><p>A single CTL may "recycle" and lyse several target cells without itself suffering damage. It is unclear how CTLs are protected from the destructive potential of the molecules they discharge. CTLs are not themselves immune to lysis, since they may themselves be the targets of other cytotoxic cells.</p><p class="headingAnchor" id="H58833546"><span class="h5">Granule exocytosis</span><span class="headingEndMark"> — </span>Following contact with the target cell, lytic granules within the CTL gather near the immunologic synapse (a process called "polarization"). The membranes of the granules fuse with the CTL membrane and release their contents directly adjacent to the target cell. CTL granules contain a variety of substances that enter the target cell and initiate apoptosis (programmed cell death). Granule contents enter the target cell through pores in the membrane created by the protein perforin, which has homology with complement factor C9. The molecules that initiate the cytotoxic process within the target cell are a family of at least 11 serine proteases called granzymes [<a href="#rid47">47</a>]. Although much of the biochemistry of granzymes is still unclear, some of their substrates may be precursor forms of caspases, a group of cytoplasmic enzymes that can trigger apoptosis [<a href="#rid47">47</a>].</p><p>CD27 is an activation marker for both T cells and B cells. It is a member of the TNF receptor superfamily (TNFRSF7). Its ligand is CD70 (TNFSF7). All of the biologic activities of the CD27–CD70 interaction are not yet well understood. It has been established, however, that EBV-infected B cells express very high levels of CD70. The interaction of CD27 on CTLs with CD70 on EBV-infected B cells greatly enhances granule-mediated cytotoxicity by CTLs [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H3066899603"><span class="h5">Fas ligand</span><span class="headingEndMark"> — </span>The other principal means of cell killing involves expression of FasL (or CD95L) on the surface of the effector CTL. If the target cell expresses the Fas molecule (CD95), ligation by FasL on the CTL will initiate a program of apoptosis in the target cell [<a href="#rid47">47</a>]. It is unknown precisely under what circumstances a CTL will use one mechanism or the other. Of course, FasL expression is not relevant for target cells that do not express Fas. Note that the CD27–CD70 interaction does not appear to enhance Fas–FasL mediated killing [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Memory T cells</span><span class="headingEndMark"> — </span>When naïve T cells are activated, some become short-lived effector T cells, while others become long-lived memory T cells. In comparison with naïve T cells, memory T cells are activated more easily and rapidly in secondary immune responses [<a href="#rid50">50</a>]. This results from alterations in surface molecules, as well as intracellular differences in signaling  (<a class="graphic graphic_table graphicRef82133" href="/z/d/graphic/82133.html" rel="external">table 4</a>) [<a href="#rid50">50</a>]. There may be many distinct functional classes of memory T cells having different migration patterns within tissues, different properties with respect to ease of stimulation and kinetics, and requirements for maintenance. However, these issues require much additional study.</p><p>Some convenient markers of memory T cells are CD45 and the CC (two adjacent cysteines) chemokine receptor CCR7. The CD45RA isoform is expressed on naïve T cells. The CD45RO isoform is expressed on activated or memory T cells. While CD45RA alone effectively distinguishes naïve CD4 cells in most circumstances, it is not as useful for CD8 cells, because a significant proportion of memory CD8 cells may revert to CD45RA expression. These markers may be used as follows [<a href="#rid51">51,52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CD45RA+ (or CD45RO-)/CCR7+ = Naïve T cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD45RA- (or CD45RO+)/CCR7+ = Central memory T cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD45RA- (or CD45RO+)/CCR7- = Effector memory T cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD45RA+ (or CD45RO-)/CCR7- = T effector memory RA-expressing cells (TEMRA). These cells occur much more commonly in the CD8 compartment, and this is sometimes called an "exhausted" type of cell, which is no longer capable of robust cytokine production or cytotoxicity. These cells are seen sometimes in the setting of chronic infections or autoimmune disease [<a href="#rid53">53</a>].</p><p></p><p>The proportion of naïve cells is high (&gt;70 to 90 percent of peripheral T cells) at birth and gradually declines with age. By late childhood or adulthood, naïve cells are &lt;50 percent of peripheral T cells  (<a class="graphic graphic_table graphicRef120438" href="/z/d/graphic/120438.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef121382" href="/z/d/graphic/121382.html" rel="external">table 6</a>) [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H17"><span class="h1">CELLULAR REGULATION OF IMMUNE RESPONSES</span><span class="headingEndMark"> — </span>Immune effector mechanisms are powerful processes of cell and tissue destruction. It is of clear benefit to maintain close control over immune system activation so that there is not unnecessary exposure to its degradative potential. T cells are critical in the regulation of both humoral (antibody) and cellular effector mechanisms. Antibody responses to the vast majority of protein and glycoprotein antigens require T cell help. Regulatory T cells (Tregs) also control specific cellular cytotoxicity [<a href="#rid55">55,56</a>]. T cell regulation is mediated by cellular contacts and soluble factors.</p><p class="headingAnchor" id="H18"><span class="h2">Positive regulation</span></p><p class="headingAnchor" id="H19"><span class="h3">Cognate T helper cell-B cell interaction</span><span class="headingEndMark"> — </span>As discussed separately, effective antibody production against T dependent antigens (most proteins and glycoproteins) requires cellular contact between B cells and T helper cells, as well as cytokine production by T cells. Naïve T cells may be activated by antigen-presenting cells (APCs). They subsequently become effectors capable of activating antigen-specific B cells that display the appropriate combination of peptide plus major histocompatibility complex (peptide-MHC). (See  <a class="medical medical_review" href="/z/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Activation of antigen-presenting cells</span><span class="headingEndMark"> — </span>The T cell-APC interaction also results in an activated "effector" APC. This cell is then capable of elaborating higher concentrations of cytokines, increased phagocytosis, and intracellular killing, as well as the capacity to activate cytotoxic T cells.</p><p class="headingAnchor" id="H21"><span class="h2">Negative regulation</span></p><p class="headingAnchor" id="H22"><span class="h3">Autoregulation via CTLA-4</span><span class="headingEndMark"> — </span>After activation, T cells reduce expression of CD28 and increase expression of cytotoxic T lymphocyte antigen 4 (CTLA-4), which has higher affinity for the ligands CD80 and CD86 (B7-1 and B7-2). This leads to loss of costimulation through CD28, resulting in cessation of proliferation and cytokine production.</p><p class="headingAnchor" id="H23"><span class="h3">Inhibition via PD-1</span><span class="headingEndMark"> — </span>Programmed cell death 1 (PD-1) is an inhibitory homolog of CD28 that is expressed late after T cell activation [<a href="#rid10">10</a>]. PD-1 interacts with the inhibitory B7 homologs programmed death ligands (PD-L) 1 and 2. Ligation of PD-1 leads to inhibition of cytokine secretion and other effector functions of T cells.</p><p class="headingAnchor" id="H24"><span class="h3">Activation-induced cell death</span><span class="headingEndMark"> — </span>Following activation, T cells expand clonally, yielding large numbers of cytokine-producing cells. These activate potent inflammatory responses to combat infection. Unchecked T cell activation could lead to malignant proliferation or autoimmune disease. Thus, one fundamental mechanism of negative regulation of T cells is activation-induced cell death (AICD) [<a href="#rid57">57</a>]. The same signals that lead to activation also set in motion a program of cell death (apoptosis) that may eventually kill the cell.</p><p>Two important receptors promoting death of activated T cells are Fas (CD95, which binds Fas ligand [FasL]) and tumor necrosis factor (TNF) receptor 2 (TNFR2 or CD120b, which binds TNF-alpha). The interactions between these ligand pairs may occur on the same cell or between different cells. That is, the mechanism may be one of "suicide" or "homicide." (See  <a class="medical medical_review" href="/z/d/html/5594.html" rel="external">"Apoptosis and autoimmune disease"</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Suppression</span><span class="headingEndMark"> — </span>Most T cells die within the thymus, either because they do not interact effectively with self-MHC molecules or they display reactivity against self-components (see  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>). However, this process is not perfect, and some self-reactive mature T cells exit the thymus and reach the periphery [<a href="#rid58">58</a>]. These cells must be inactivated (ie, made anergic) in order to prevent autoimmune disease. In addition, there must be a process to extinguish a protective immune response when it is no longer necessary. Mechanisms of immune suppression or regulation serve both of these functions.</p><p class="headingAnchor" id="H3210674978"><span class="h3">Role of cytokines in negative feedback</span><span class="headingEndMark"> — </span>In addition to positive feedback loops involving cytokines, many negative feedback signals downregulate the immune system. This prevents an inflammatory response from overwhelming and harming the host. A number of cytokines  (<a class="graphic graphic_table graphicRef69910" href="/z/d/graphic/69910.html" rel="external">table 1</a>) and small-molecule mediators can dampen the immune response.</p><p class="bulletIndent1"><span class="glyph">●</span>Prostaglandins (such as prostaglandin E2) produced by macrophages can inhibit a variety of functions, including the induction of human leukocyte antigen (HLA) DR on macrophages and the production of interferon (IFN) gamma by T cells [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transforming growth factor (TGF) beta is a potent suppressor of T cell activation and can decrease T cell proliferation and cytokine production [<a href="#rid60">60</a>]. It also decreases the number of interleukin (IL) 1 receptors, thereby making cells less sensitive to other cytokines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IL-10 deactivates macrophages, which in turn decreases production of cytokines by T cells [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IL-35 inhibits the amplification of T helper cell type 17 (Th17) cells [<a href="#rid62">62</a>].</p><p></p><p>These control mechanisms are critical elements for keeping the inflammatory response in check and maintaining homeostasis. Their importance can be demonstrated in animals that lack some of these elements. As an example, rodents that lack the TGF-beta gene have a generalized inflammatory disease due to the absence of its suppressive influence [<a href="#rid63">63</a>]. This observation illustrates that cytokines are as important to the termination of the immune response as they are to its initiation.</p><p class="headingAnchor" id="H28"><span class="h2">Gamma-delta T cells</span><span class="headingEndMark"> — </span>T cells expressing the gamma-delta (TCR1) form of the TCR are a distinct functional class whose physiologic role is not yet understood. In normal individuals, approximately 1 to 5 percent of circulating T cells are TCR1+, the great majority of these cells are "double negative" (DN or CD4-CD8-) [<a href="#rid64">64</a>]. As in blood, the TCR1/TCR2 ratio is approximately 1 in 50 in secondary lymphoid tissues. However, in other locations, such as gut epithelium, the ratio is 1 in 5. (See  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p>Gamma-delta T cells have the capacity to interact with a variety of low-molecular-weight alkyl phosphates [<a href="#rid64">64</a>]. Many such compounds are found in mycobacterial cytoplasm. Alkylamines also stimulate gamma-delta T cells. The restricting elements for gamma-delta T cell antigen recognition are generally not classic MHC antigens but nonclassic MHC class I-like molecules, such as CD1, Qa, TL, or the MHC class I chain-related genes MICA and B (the latter via natural killer group 2 D [NKG2D]) [<a href="#rid48">48,64</a>].</p><p>Although gamma-delta cells may be stimulated by dendritic cells (DCs) and other professional APCs, their ability to interact with nonclassic MHC class I molecules may permit them to respond to antigens in situ when presented by other types of cells, such as intestinal enterocytes. The requirements for costimulation for gamma-delta cell activation are not yet clear. Some gamma-delta cells express CD28, but other mechanisms may operate in CD28-negative populations.</p><p>TCR1+ T cells are expanded in a variety of infections, such as tuberculosis, leprosy, malaria, toxoplasmosis, Epstein-Barr virus (EBV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), and Lyme disease [<a href="#rid64">64</a>]. In some murine models, this activity cannot be completely compensated by TCR2+ cells. This has not been clearly shown for humans. TCR1+ T cells are speculated to have some role in modulating or limiting inflammation initiated by TCR2+ T cells. Gamma-delta T cells do not appear to contribute to the memory T cell pool.</p><p>Gamma-delta T cells having phenotypes similar to T helper cell type 1 (Th1), T helper cell type 2 (Th2), and cytotoxic and regulatory T cells (Tregs) have all been described [<a href="#rid64">64</a>]. In some cases, these cells are CD4 or CD8 positive, indicating that they are not generally representative of TCR1+ cells. On the other hand, some are the more common DN type. Some have speculated that TCR1+ T cells are a more primitive form of cellular immunity and that they represent a "first line of defense" during infection. Much remains to be learned regarding the physiologic role(s) of gamma-delta T cells.</p><p class="headingAnchor" id="H176473472"><span class="h2">Natural killer T cells</span><span class="headingEndMark"> — </span>Natural killer T (NKT) cells are characterized by the surface expression of a single antigen receptor with an invariant V-J segment that recognizes glycolipids in combination with CD1d, an MHC I-like molecule. These cells express either CD4 or are negative for both CD4 and CD8. NKT cells are found in the thymus, spleen, liver, and bone marrow. Binding of NKT cells to the target antigen typically leads to IFN-gamma production, which in turn can upregulate NK and CD8 T cell activity. This combined adjuvant action has led to consideration for application of NKT cells in the treatment of advanced malignancies due to the ability to enhance destruction of malignant cells that do and do not express MHC I [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell-mediated immunity</strong> – T cells are the effectors of antigen-specific cell-mediated immunity (CMI). CMI is important in the elimination of cells infected with pathogens that replicate intracellularly (eg, viruses, mycobacteria, and some bacteria) and cells exhibiting aberrant differentiation (eg, neoplasms). CMI also destroys allogeneic cells (graft rejection). In addition, it is involved in cellular autoimmune responses, as well as type IV allergic reactions to drugs and contact dermatitis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response initiation by APCs</strong> – T cell responses are initiated by antigen-presenting cells (APCs), primarily dendritic cells (DCs). (See <a class="local">'Antigen-presenting cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Two-signal activation</strong> – T cell activation is thought to occur via a two-signal model. Signal 1 derives from contact of the T cell receptor (TCR)-CD3 complex with a major histocompatibility complex (MHC)-peptide complex. Signal 2 derives from costimulatory pathways. (See <a class="local">'T cell activation and functions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Helper T cells</strong> – Helper T (Th) cells may be subdivided into effector populations with distinct cytokine secretion profiles  (<a class="graphic graphic_figure graphicRef58150" href="/z/d/graphic/58150.html" rel="external">figure 3</a> and <a class="graphic graphic_table graphicRef69910" href="/z/d/graphic/69910.html" rel="external">table 1</a>). (See <a class="local">'Cytokine profiles and functions of CD4+ T helper cell subsets'</a> above and <a class="local">'Cytokines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytotoxic T cells</strong> – Most cytotoxic T lymphocytes (CTLs) express the alpha-beta TCR heterodimer with the CD8 molecule and recognize peptide antigens in association with MHC class I. These cells kill target cells by two principal mechanisms: exocytosis of cytolytic granules containing perforin, granzymes, and other cytotoxic molecules and the interaction of Fas ligand (FasL) on CTLs with Fas expressed on target cells. (See <a class="local">'Cytotoxic T lymphocyte function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cell regulation</strong> – T cells are critical in the regulation of both humoral (antibody) and cellular effector mechanisms. Antibody responses to most protein and glycoprotein antigens require T cell help. Regulatory T cells (Tregs) also control specific cellular cytotoxicity. T cell regulation is mediated by cellular contacts and soluble factors. The cellular immune response can be amplified through positive feedback loops or dampened through negative regulation. (See <a class="local">'Cellular regulation of immune responses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gamma-delta T cells</strong> – Most gamma-delta T cells do not express either CD4 or CD8. However, they can be divided into functional subsets similar to helper, cytotoxic, and regulatory T cells that express the alpha-beta receptor. The ligands for gamma-delta TCRs in most cases are not peptide MHC complexes but rather pathogen-associated molecules that interact by different mechanisms with MHC-like molecules. (See <a class="local">'Gamma-delta T cells'</a> above.)</p><p></p><p class="headingAnchor" id="H3769629392"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Francisco A Bonilla, MD, PhD, who contributed as an author to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009; 10:1237.</a></li><li><a class="nounderline abstract_t">Randolph GJ. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol 2001; 13:267.</a></li><li><a class="nounderline abstract_t">Strieter RM, Koch AE, Antony VB, et al. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994; 123:183.</a></li><li><a class="nounderline abstract_t">Dyer DP, Medina-Ruiz L, Bartolini R, et al. Chemokine Receptor Redundancy and Specificity Are Context Dependent. Immunity 2019; 50:378.</a></li><li><a class="nounderline abstract_t">Jenkins MK, Khoruts A, Ingulli E, et al. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 2001; 19:23.</a></li><li><a class="nounderline abstract_t">Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol 2004; 4:325.</a></li><li><a class="nounderline abstract_t">Kummerow C, Junker C, Kruse K, et al. The immunological synapse controls local and global calcium signals in T lymphocytes. Immunol Rev 2009; 231:132.</a></li><li><a class="nounderline abstract_t">Krogsgaard M, Li QJ, Sumen C, et al. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature 2005; 434:238.</a></li><li><a class="nounderline abstract_t">Salmond RJ, Filby A, Qureshi I, et al. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009; 228:9.</a></li><li><a class="nounderline abstract_t">Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009; 229:5.</a></li><li><a class="nounderline abstract_t">Schmitt N, Ueno H. Regulation of human helper T cell subset differentiation by cytokines. Curr Opin Immunol 2015; 34:130.</a></li><li><a class="nounderline abstract_t">Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051.</a></li><li><a class="nounderline abstract_t">Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW. Th1 and Th2 cytokines in organ transplantation: paradigm lost? Crit Rev Immunol 1999; 19:155.</a></li><li><a class="nounderline abstract_t">Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129.</a></li><li><a class="nounderline abstract_t">Jung S, Littman DR. Chemokine receptors in lymphoid organ homeostasis. Curr Opin Immunol 1999; 11:319.</a></li><li><a class="nounderline abstract_t">Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187:875.</a></li><li><a class="nounderline abstract_t">Collins A, Littman DR, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol 2009; 9:106.</a></li><li><a class="nounderline abstract_t">Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol 2009; 9:125.</a></li><li><a class="nounderline abstract_t">Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307:430.</a></li><li><a class="nounderline abstract_t">Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348.</a></li><li><a class="nounderline abstract_t">Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145.</a></li><li><a class="nounderline abstract_t">Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227.</a></li><li><a class="nounderline abstract_t">Nakamura T, Kamogawa Y, Bottomly K, Flavell RA. Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol 1997; 158:1085.</a></li><li><a class="nounderline abstract_t">Goswami R, Jabeen R, Yagi R, et al. STAT6-dependent regulation of Th9 development. J Immunol 2012; 188:968.</a></li><li><a class="nounderline abstract_t">Ramming A, Druzd D, Leipe J, et al. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood 2012; 119:4665.</a></li><li><a class="nounderline abstract_t">Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends Immunol 2014; 35:61.</a></li><li><a class="nounderline abstract_t">Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010; 33:192.</a></li><li><a class="nounderline abstract_t">Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 2009; 127:450.</a></li><li><a class="nounderline abstract_t">Awe O, Hufford MM, Wu H, et al. PU.1 Expression in T Follicular Helper Cells Limits CD40L-Dependent Germinal Center B Cell Development. J Immunol 2015; 195:3705.</a></li><li><a class="nounderline abstract_t">Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888.</a></li><li><a class="nounderline abstract_t">Crome SQ, Wang AY, Levings MK. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010; 159:109.</a></li><li><a class="nounderline abstract_t">Cosmi L, Liotta F, Maggi E, et al. Th17 cells: new players in asthma pathogenesis. Allergy 2011; 66:989.</a></li><li><a class="nounderline abstract_t">Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol 2008; 28:660.</a></li><li><a class="nounderline abstract_t">Plank MW, Kaiko GE, Maltby S, et al. Th22 Cells Form a Distinct Th Lineage from Th17 Cells In Vitro with Unique Transcriptional Properties and Tbet-Dependent Th1 Plasticity. J Immunol 2017; 198:2182.</a></li><li><a class="nounderline abstract_t">Basu R, O'Quinn DB, Silberger DJ, et al. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 2012; 37:1061.</a></li><li><a class="nounderline abstract_t">Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009; 10:385.</a></li><li><a class="nounderline abstract_t">King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008; 26:741.</a></li><li><a class="nounderline abstract_t">King C. New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009; 9:757.</a></li><li><a class="nounderline abstract_t">Schmitt N, Morita R, Bourdery L, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 2009; 31:158.</a></li><li><a class="nounderline abstract_t">Rasheed AU, Rahn HP, Sallusto F, et al. Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol 2006; 36:1892.</a></li><li><a class="nounderline abstract_t">Wu H, Deng Y, Zhao M, et al. Molecular Control of Follicular Helper T cell Development and Differentiation. Front Immunol 2018; 9:2470.</a></li><li><a class="nounderline abstract_t">Belizário JE, Brandão W, Rossato C, Peron JP. Thymic and Postthymic Regulation of Naïve CD4(+) T-Cell Lineage Fates in Humans and Mice Models. Mediators Inflamm 2016; 2016:9523628.</a></li><li><a class="nounderline abstract_t">Carrier Y, Yuan J, Kuchroo VK, Weiner HL. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol 2007; 178:179.</a></li><li><a class="nounderline abstract_t">Zhang S, Zhang H, Zhao J. The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys Res Commun 2009; 384:405.</a></li><li><a class="nounderline abstract_t">Kitchen SG, Jones NR, LaForge S, et al. CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection. Proc Natl Acad Sci U S A 2004; 101:8727.</a></li><li><a class="nounderline abstract_t">Fooksman DR, Grönvall GK, Tang Q, Edidin M. Clustering class I MHC modulates sensitivity of T cell recognition. J Immunol 2006; 176:6673.</a></li><li><a class="nounderline abstract_t">Henkart PA, Catalfamo M. CD8+ effector cells. Adv Immunol 2004; 83:233.</a></li><li><a class="nounderline abstract_t">Rancan C, Schirrmann L, Hüls C, et al. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog 2015; 11:e1004906.</a></li><li><a class="nounderline abstract_t">Yamada S, Shinozaki K, Agematsu K. Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin Exp Immunol 2002; 130:424.</a></li><li><a class="nounderline abstract_t">Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity 2009; 31:859.</a></li><li><a class="nounderline abstract_t">Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol 2009; 39:2076.</a></li><li><a class="nounderline abstract_t">Siegel AM, Heimall J, Freeman AF, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 2011; 35:806.</a></li><li><a class="nounderline abstract_t">Fagin U, Pitann S, Gross WL, Lamprecht P. Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener's). Arthritis Res Ther 2012; 14:R73.</a></li><li><a class="nounderline abstract_t">Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973.</a></li><li><a class="nounderline abstract_t">Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009; 15:1879.</a></li><li><a class="nounderline abstract_t">Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229:41.</a></li><li><a class="nounderline abstract_t">Zhang J, Xu X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol 2004; 1:186.</a></li><li><a class="nounderline abstract_t">Parish IA, Heath WR. Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells. Immunol Cell Biol 2008; 86:146.</a></li><li><a class="nounderline abstract_t">Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum 1987; 30:864.</a></li><li><a class="nounderline abstract_t">Wahl SM, Allen JB, Wong HL, et al. Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium. J Immunol 1990; 145:2514.</a></li><li><a class="nounderline abstract_t">Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993; 11:165.</a></li><li><a class="nounderline abstract_t">Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37:3021.</a></li><li><a class="nounderline abstract_t">Diebold RJ, Eis MJ, Yin M, et al. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A 1995; 92:12215.</a></li><li><a class="nounderline abstract_t">Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18:975.</a></li><li><a class="nounderline abstract_t">Metelitsa LS. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin Immunol 2011; 140:119.</a></li><li><a class="nounderline abstract_t">Jahnke S, Schmid H, Secker KA, et al. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner. Front Immunol 2019; 10:1542.</a></li></ol></div><div id="topicVersionRevision">Topic 3980 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915624" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dendritic cell subsets in primary and secondary T cell responses at body surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502161" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8301193" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30784579" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chemokine Receptor Redundancy and Specificity Are Context Dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11244029" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : In vivo activation of antigen-specific CD4 T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122198" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19754894" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The immunological synapse controls local and global calcium signals in T lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15724150" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19290918" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19426211" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mechanisms of costimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25879814" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Regulation of human helper T cell subset differentiation by cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18563156" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Induction and effector functions of T(H)17 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10352902" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Th1 and Th2 cytokines in organ transplantation: paradigm lost?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419219" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10375556" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chemokine receptors in lymphoid organ homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500790" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165227" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : RUNX proteins in transcription factor networks that regulate T-cell lineage choice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19151747" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15662016" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2419430" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2523712" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8011282" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lymphokine production by human T cells in disease states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9013946" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Polarization of IL-4- and IFN-gamma-producing CD4+ T cells following activation of naive CD4+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22180613" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : STAT6-dependent regulation of Th9 development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22446486" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24215739" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Th9 cells, new players in adaptive immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20674401" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19604299" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Th9 and allergic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26363052" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : PU.1 Expression in T Follicular Helper Cells Limits CD40L-Dependent Germinal Center B Cell Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710487" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interleukin-17 and type 17 helper T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19912252" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21375540" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Th17 cells: new players in asthma pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18810613" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Interplay between effector Th17 and regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28100680" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Th22 Cells Form a Distinct Th Lineage from Th17 Cells In Vitro with Unique Transcriptional Properties and Tbet-Dependent Th1 Plasticity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200827" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252490" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cytokine-secreting follicular T cells shape the antibody repertoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173374" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : T follicular helper (TFH) cells in normal and dysregulated immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19855402" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New insights into the differentiation and function of T follicular helper cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19592276" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791882" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30410493" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Molecular Control of Follicular Helper T cell Development and Differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27313405" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Thymic and Postthymic Regulation of Naïve CD4(+) T-Cell Lineage Fates in Humans and Mice Models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182553" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19410556" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The role of CD4 T cell help for CD8 CTL activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173593" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709826" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clustering class I MHC modulates sensitivity of T cell recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15135633" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : CD8+ effector cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26067064" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12452832" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20064446" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diversity in T cell memory: an embarrassment of riches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19672903" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22118528" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22490506" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Increased frequency of CCR4+ and CCR6+ memory T-cells including CCR7+CD45RAmed very early memory cells in granulomatosis with polyangiitis (Wegener's).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14610491" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19519430" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Regulatory T cells: major players in the tumor microenvironment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19426214" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219166" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Activation-induced cell death in T cells and autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18227854" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3115274" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2212650" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386517" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Interleukin-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17874423" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618872" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837080" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : [gamma][delta]cells: a right time and a right place for a conserved third way of protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21095162" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31354710" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
